Why the study?
Does endogenous activation of cardiac PKC-epsilon protect against hyperglycemic cell injury and left ventricular dysfunction in a mouse model of streptozotocin-induced diabetes?
Population
Genetically engineered mice with cardiac-specific expression of the PKC-epsilon translocation activator with…
Design
Preclinical
Authors
Loading...
Hypothesis-generating for PKC-epsilon activation in diabetic cardiomyopathy; prospective human studies required before clinical consideration.
Does endogenous activation of cardiac PKC-epsilon protect against hyperglycemic cell injury and left ventricular dysfunction in a mouse model of streptozotocin-induced diabetes?
Activation of endogenous PKC-epsilon in the diabetic heart promotes cell survival, reduces oxidative stress, and preserves left ventricular function in a preclinical model.
Malhotra et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: